Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock Holdings Lessened by Diametric Capital LP

Diametric Capital LP reduced its stake in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 42.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 43,146 shares of the company’s stock after selling 32,379 shares during the quarter. Diametric Capital LP’s holdings in Lifecore Biomedical were worth $321,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. DCF Advisers LLC lifted its position in Lifecore Biomedical by 87.2% in the 4th quarter. DCF Advisers LLC now owns 539,989 shares of the company’s stock worth $4,012,000 after buying an additional 251,511 shares in the last quarter. 272 Capital LP increased its stake in shares of Lifecore Biomedical by 511.1% in the third quarter. 272 Capital LP now owns 143,480 shares of the company’s stock worth $707,000 after acquiring an additional 120,002 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Lifecore Biomedical by 10.3% during the third quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock worth $2,948,000 after acquiring an additional 55,703 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Lifecore Biomedical by 2,640.5% during the third quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock valued at $268,000 after purchasing an additional 52,414 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Lifecore Biomedical in the third quarter valued at about $207,000. 83.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lifecore Biomedical

In other news, CEO Paul Josephs acquired 17,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The stock was acquired at an average cost of $5.74 per share, with a total value of $97,580.00. Following the acquisition, the chief executive officer now owns 559,717 shares in the company, valued at approximately $3,212,775.58. This represents a 3.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 32.20% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Stephens restated an “equal weight” rating and issued a $6.00 price objective on shares of Lifecore Biomedical in a report on Friday, January 3rd.

Lifecore Biomedical Trading Down 0.1 %

Lifecore Biomedical stock opened at $7.03 on Wednesday. Lifecore Biomedical, Inc. has a one year low of $3.68 and a one year high of $7.99. The company’s fifty day moving average price is $6.16 and its two-hundred day moving average price is $6.23. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The company has a market capitalization of $260.29 million, a price-to-earnings ratio of -12.55 and a beta of 0.96.

Lifecore Biomedical (NASDAQ:LFCR) last issued its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. On average, analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.